Compare · ABT vs PLXP
ABT vs PLXP
Side-by-side comparison of Abbott Laboratories (ABT) and PLx Pharma Inc. (PLXP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PLXP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $182.09B, about 1158.0x PLXP ($157.2M).
- ABT has hit the wire 10 times in the past 4 weeks while PLXP has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 2 for PLXP).
- Company
- Abbott Laboratories
- PLx Pharma Inc.
- Price
- $105.26-0.30%
- $0.09-25.31%
- Market cap
- $182.09B
- $157.2M
- 1M return
- -3.14%
- -
- 1Y return
- -18.64%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 2
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
PLx Pharma Inc.
PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.
Latest ABT
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)
- EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
Latest PLXP
- SEC Form 15-12G filed by PLx Pharma Inc.
- PLx Pharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits
- PLx Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- PLx Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- PLx Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- PLx Pharma Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- PLx Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- PLx Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 25-NSE filed by PLx Pharma Inc.
- PLx Pharma Says Each Of Debtors Continue To Operate Business As 'Debtor-In-Possession' Under Jurisdiction of Bankruptcy Court